GL
OCUL icon

Graypoint LLC’s Ocular Therapeutix OCUL Stock Holding History

Graypoint LLC’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$234K Buy
25,194
+5,000
+25% +$39.1K 0.01% 489
2025
Q1 		$148K Buy
+20,194
New +$155K 0.01% 499

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Graypoint LLC's OCUL Position: Q2 2025 in Review

Graypoint LLC increased its Ocular Therapeutix (OCUL) stake by 25% in Q2 2025, buying an estimated $39.1K and bringing the position to 25,194 shares worth $234K. The position accounts for 0.01% of the portfolio, ranked #489.

Graypoint LLC first reported a position in OCUL in Q1 2025 and has held it in 2 quarters since. 186 funds tracked by Wall St. Rank hold OCUL as of Q2 2025.

  • Graypoint LLC held 25,194 shares of Ocular Therapeutix worth $234K as of Q2 2025.
  • Graypoint LLC bought 5,000 Ocular Therapeutix shares in Q2 2025, an estimated $39.1K.
  • Ocular Therapeutix made up 0.01% of Graypoint LLC's portfolio in Q2 2025, its #489 holding.
  • Graypoint LLC first reported a position in Ocular Therapeutix in Q1 2025 and has held it in 2 quarters since.
  • 186 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2025.

Based on Graypoint LLC's 13F filing for Q2 2025, filed 15 Jul 2025.